|
Patent landscape, scope, and claims: |
Patent 11,083,712 (US) scope and claims: A US method-of-treatment and composition/device estate directed to self-administered, prefilled, single-use autoinjector delivery of an “ergoline derivative” headache medicament, centered on dihydroergotamine (DHE) or DHE salts at defined concentration ranges, with non-adjustable dose/dosing mechanism, defined needle/subcutaneous configuration, defined onset-timing administration windows, and specific auto-injector trigger/dosing mechanics and safety-cap removal techniques.
United States Patent 11,083,712: What is the invention and what does it cover?
Core invention in one line: Preassembled, prefilled, single-use injection delivery of an ergoline-derivative medicament for treating headache, using an autoinjector whose trigger advances the syringe and needle and then injects a non-user-adjustable dose, with emphasis on DHE (including DHE mesylate) at specified mg/mL concentrations and dose ranges.
Claim set architecture (what the patent is actually doing)
The independent/composition claim (Claim 25) and method claim (Claim 1) split the estate into three tightly coupled protection layers:
-
Therapeutic use layer (headache treatment)
- Method of treating a person with a headache using an ergoline derivative medicament via a prefilled autoinjector injection workflow.
- Explicit headache-type enumerations (migraine, tension-type, cluster; hemicrania continua, NDPH, post-traumatic, medication-overuse).
-
Drug substance + concentration layer (DHE-specific concentration windows)
- Concentration range about 0.3 mg/mL to about 1.5 mg/mL across the independent method and composition claim.
- DHE species: dihydroergotamine and pharmaceutically acceptable salts, with dependent claims spotlighting DHE mesylate and sub-ranges (notably ~1 mg/mL; 0.5–1.4; 0.8–1.2; 1.5 mg/mL).
-
Device mechanics + usability layer (autoinjector and trigger/safety interaction)
- Trigger mechanism actuates to advance syringe and injection needle and discharge medicament.
- Dose amount and dosing mechanism not adjustable by the user.
- Additional dependents narrow to:
- Autoinjector self-administered at headache onset
- Subcutaneous needle parameters (25–30 gauge)
- Administration within time windows after onset (≤2, ≤5, ≤10, ≤20 minutes)
- Auto-injector syringe visual check
- Specific spring/piston-rod trigger architecture
- Specific safety-cap removal grips/wedges (thenar, axilla/cubital/popliteal fossa, seat-wedging posterior thigh method)
What patents protect autoinjector delivery of dihydroergotamine for migraine and other headaches? (Where 11,083,712 is strongest)
11,083,712’s protection focus is narrow but high-leverage because it ties together: (a) the drug identity/concentration range, (b) the non-adjustable autoinjector delivery workflow, and (c) specific time-to-administration and usability mechanics.
Where claim coverage is most enforceable (high “literal overlap” risk)
The estate is most likely to bite when an ANDA/BLA-analog, competitor device design, or formulation replicates all or most of the following:
- Ergoline derivative is DHE or DHE salt (especially DHE mesylate)
- DHE concentration is within ~0.3 mg/mL to ~1.5 mg/mL
- Autoinjector uses:
- trigger advances syringe and hollow needle
- injection needle penetrates injection site while device maintained
- medicament dispensed through needle
- User cannot adjust dose/dosing mechanism
- Needle is set for subcutaneous injection with 25–30 gauge
- Administration occurs very quickly after onset (≤2/5/10/20 minutes dependents)
- Some added claim value (if copied):
- syringe visible for pre-trigger visual check
- syringe visible during maintaining on injection site
- safety-cap removal techniques
- specific mechanical sequence (piston rod released from retainer; spring compressed)
- auto-injector discharge includes dose amount 0.5 mg to 3 mg
Where it is weaker (easier design-around)
The estate becomes more design-aroundable when competitors:
- use a different route (IV instead of SC),
- use a different class of active than an ergoline derivative (or avoid DHE family),
- place DHE concentration outside the claimed mg/mL windows,
- provide user-adjustability (or variable dose settings),
- use a different actuation concept that does not match the trigger-to-advance-and-discharge scheme (or omits the defined “dosing mechanism advances the syringe and needle” relationship),
- avoid copying the safety-cap removal technique language (though device mechanics can be the dominant overlap in litigation).
What is the scope of Claim 1 (method of treating headache with DHE ergoline derivative in an autoinjector)?
Claim 1 (method) key elements
- Treating a headache in a person by administering an ergoline derivative medicament using:
- preassembled, prefilled, single-use delivery device
- Workflow:
- place device against injection site
- actuate trigger mechanism
- trigger causes dosing mechanism to:
- advance syringe and injection needle
- discharge medicament through injection needle
- maintain device against injection site while needle penetrates and injects medicament
- Medicament concentration:
- 0.3 mg/mL to 1.5 mg/mL ergoline derivative
- Dependent claim narrowing expands:
- non-adjustable dosing mechanism and dose amount (Claims 2–3)
- DHE identity and salts (Claims 4–7)
- DHE concentration examples (Claim 6: ~1 mg/mL)
- DHE dose range delivered (Claim 7: 0.5 mg to 3 mg)
- autoinjector self-administered “while onset” (Claim 8)
- headache subtypes (Claim 9–10)
- needle gauge and SC injection (Claim 11)
- administration within time windows (Claim 12–15)
- specific safety-cap removal techniques (Claims 16–20)
- specific dosing mechanism mechanics (Claims 21–22)
- syringe visibility checks (Claims 23–24)
Interpretation hotspots (what will drive claim construction disputes)
- “preassembled, prefilled, single use delivery device”
- Competitors with refillable cartridges or multi-use platforms face potential non-infringement.
- “dosing mechanism… not adjustable by the user”
- Many autoinjectors include fixed-dose compliance; those that include selectable dosing are at risk of falling outside.
- “maintaining the delivery device against the injection site, while the injection needle penetrates”
- Design that separates actuation from needle penetration timing may change infringement outcomes.
- “about” ranges
- mg/mL boundaries will be tested using ordinary skill construction and tolerance concepts; risk concentrates near the claimed borders.
How does Claim 25 broaden protection to an ergoline derivative medicament in an autoinjector device?
Claim 25 (composition/device) key elements
- An ergoline derivative containing medicament comprising:
- Medicament disposed in an auto-injector device with:
- syringe containing medicament
- hollow injection needle coupled to distal end
- dosing mechanism adjacent to proximal end
- trigger mechanism coupled to dosing mechanism
- Trigger actuation causes dosing mechanism to:
- advance syringe and needle
- discharge medicament through injection needle
- DHE concentration:
Why Claim 25 matters strategically
Claim 25 converts the method into an enforceable product concept:
- If the device is sold with the claimed drug concentration and mechanical arrangement, infringement can occur without proving a specific “method of treating” fact pattern.
- This is the claim class most directly usable in device+drug combined litigation and in licensing negotiations.
What formulation and concentration parameters are claimed (DHE concentration in mg/mL and dose mg)?
Independent concentration range
- ~0.3 mg/mL to ~1.5 mg/mL ergoline derivative (Claims 1 and 25)
Dependent concentration refinements
- ~1 mg/mL (Claim 6 and Claim 27)
- ~1.5 mg/mL (Claim 28)
- 0.5 to 1.4 mg/mL (Claim 29)
- 0.8 to 1.2 mg/mL (Claim 30)
Dose amount ranges
- DHE dose delivered:
- 0.5 mg to 3 mg (Claim 31)
- One explicit exemplar composition (Claim 36):
- 1.0 mg DHE mesylate
- 49.0 mg ethanol
- 150 mg glycerin
- 800 mg water for injection
- buffer comprising sodium hydroxide and/or methane sulfonic acid
- pH targeted 3.4 to 4.9
Excipients and functional formulation components
Claim 32 covers general functional additives:
- tonicity adjusting agents
- buffers
- antioxidants
- stabilizers
- nonionic wetting/clarifying agents
- viscosity modifiers
Claim 33 adds a specific solvent system element:
- alcohol, glycerin, water for injection
Claims 34–35 focus pH/buffer adjusters:
- buffer or pH adjusting agent
- sodium hydroxide or methane sulfonic acid
Practical litigation leverage
A competitor formulation is easiest to attack if it:
- stays within concentration windows,
- uses the same DHE salt form (mesylate),
- and uses similar pH/excipient systems that map to Claim 36.
If a competitor changes ethanol/glycerin system or pH targets, Claims 32–35 may still capture “one or more” categories, but Claim 36 is a tighter exemplar.
What device mechanics and user-action features are claimed (autoinjector trigger and safety cap)?
Trigger-to-injection sequence (device operation)
Claim 1 and Claim 25 require a specific operational relationship:
- trigger actuation causes dosing mechanism to advance:
- and discharge medicament through the needle
Non-adjustability constraints
- dosing mechanism not adjustable by the user (Claim 2)
- dose amount not adjustable by the user (Claim 3)
These are often dispositive for design-around because many competitors offer selectable dosing or re-arming features.
Actuation architecture (spring/piston-rod)
Claims 21–22 narrow further:
- piston rod retained in armed position and keeping spring under compression
- piston rod contacts syringe plunger
- trigger releases piston rod from retainer
- spring and piston rod urge syringe toward injection site
- at end of syringe travel, spring/piston rod drives plunger travel through syringe to dispense medicament
Syringe visibility (human factors)
- syringe viewable inside autoinjector (Claims 23–24)
- visual check prior to trigger
- visual check while maintaining device against injection site
Safety cap removal technique claims (highly specific)
Claims 16–20 cover safety cap removal with particular grip/motor movement descriptions:
- predominately gross motor movements (Claim 17)
- thenar grip for safety cap and opposite hand grip for handle (Claim 18)
- alternative grips using axilla/cubital fossa/popliteal fossa with flared portion (Claim 19)
- wedging safety cap between posterior thigh and seat surface and pulling handle using one or both hands (Claim 20)
These are the most likely to create evidentiary and construction disputes, but if competitors copy the user ergonomics, they become strong additional infringement hooks.
When does the drug need to be administered after headache onset to meet dependent claims?
Dependent claims embed administration timing windows after onset:
- within 2 minutes or less (Claim 12)
- within 5 minutes or less (Claim 13)
- within 10 minutes or less (Claim 14)
- within 20 minutes or less (Claim 15)
These time limitations affect enforceability depending on how the claims are asserted. If a defendant markets the product for immediate self-administration and real-world use aligns with the windows, timing becomes a factual and marketing-evidence question.
What needle configuration is claimed for delivery (subcutaneous injection, gauge)?
Claim 11 narrows the injection needle:
- “length sufficient for subcutaneous injection”
- 25–30 gauge
This is an additional constraint that can enable design-around if competitors use different gauge needles or different injection depth configurations.
How strong is the patent estate around 11,083,712’s core concept (DHE autoinjector with fixed-dose, non-adjustable delivery)?
Based on Claim 1/25 structure alone, the strength profile is:
Strength drivers
- Two independent-ish protection axes:
- method-of-use (Claim 1)
- product/device composition (Claim 25)
- Tight coupling of drug concentration range with delivery device operating sequence
- Multiple nested dependent claims:
- DHE salt form, specific concentration exemplars, dose range, SC needle gauge, administration timing, ergonomic safety-cap removal, spring-driven trigger mechanics
Weakness drivers for challengers
- If a competitor product matches even portions of the coupling, they may still capture dependent claim variations unless they escape the core concentration window or the fixed-dose/non-adjustable constraints.
- The safety-cap grip dependents are narrow, but they are additive, not substitutive.
Generic entry risk: What generic, biosimilar, or alternative device/manufacturing scenarios would most likely avoid infringement?
Likeliest non-infringement paths
- Use an ergoline derivative other than DHE (or avoid ergoline derivative entirely)
- Keep DHE concentration outside 0.3–1.5 mg/mL and outside major subranges (0.5–1.4; 0.8–1.2; ~1)
- Deliver via non-autoinjector or non-preassembled, non-prefilled, or non-single-use configuration
- Provide user-adjustability:
- adjustable dosing mechanism
- selectable dose amount
- Change needle gauge or avoid SC configuration matching 25–30 gauge / required length
- Avoid the specific trigger architecture relationship:
- dosing mechanism that advances syringe and needle and discharges via hollow injection needle is central
Most likely “at risk” entry paths
- A DHE autoinjector with fixed dosing, DHE mesylate at ~1 mg/mL, SC 25–30 gauge needle, and spring/rod trigger mechanics.
- Any product whose label or IFU emphasizes self-administration at onset within minutes may create timing overlap with the dependent method claims.
What patent litigation questions does 11,083,712 raise in practice?
Because the estate includes both a method claim and a device/product claim, litigation typically bifurcates:
- Infringement theory A: product/device structure and drug composition satisfy Claim 25.
- Infringement theory B: real-world use and labeling satisfy Claim 1 dependent limitations (onset timing, headache-type selection, SC needle specifics, visual check steps if relevant).
The most contentious issues in such disputes typically become:
- claim construction for “about” concentration and “non-adjustable by the user”
- whether the trigger “causes dosing mechanism to advance syringe and needle” in the same mechanical and functional manner
- whether the marketed use maps to the dependent timing windows and headache subtypes
Key Takeaways
- 11,083,712 is a tightly coupled DHE autoinjector patent: it links headache treatment, DHE (or DHE salt), DHE concentration (0.3–1.5 mg/mL), and fixed-dose non-user-adjustable autoinjector mechanics.
- Claim 1 (method) protects a use workflow including onset timing options (≤2/5/10/20 minutes), SC delivery (25–30 gauge), and specific user actuation elements.
- Claim 25 (device/composition) enables stronger product-level enforcement by requiring the DHE concentration and autoinjector mechanical relationship in the same claim.
- Design-around is most feasible by escaping the drug concentration window, the fixed-dose non-adjustability requirement, or the SC/needle-gauge + trigger-to-advance-and-discharge mechanism coupling.
- The formulation claims include an explicit exemplar (Claim 36) with DHE mesylate 1.0 mg and pH 3.4–4.9, plus broader excipient categories that may capture many conventional DHE injectable compositions.
FAQs
-
Does 11,083,712 require dihydroergotamine specifically, or does it cover other ergoline derivatives?
Claim 1 and Claim 25 are framed around “ergoline derivative,” with DHE/accepted salts called out in dependent claims and explicitly in Claim 25.
-
How much room exists to change the DHE concentration and avoid the independent range?
The independent concentration window is “about 0.3 mg/mL to about 1.5 mg/mL,” with multiple dependent subranges (notably ~1 mg/mL, 0.5–1.4 mg/mL, 0.8–1.2 mg/mL).
-
Can a competing autoinjector avoid infringement by making the dose adjustable by the user?
The method includes dependent claims requiring the dosing mechanism and dose amount to be not adjustable by the user.
-
Are timing-from-onset limitations required in every claim?
The “within X minutes of onset” limits are dependent, so they attach only to the relevant dependent claims.
-
What claims are most sensitive to the ergonomics of safety-cap removal?
Safety-cap removal grip and wedging approaches are in dependent Claims 16–20 and are highly specific to user technique.
References
- US Patent No. 11,083,712 (United States), claims as provided by user.
More… ↓
⤷ Start Trial
|
